Currency Currency Currency
CSCI Net Impact Change Impact Constant Currency
Sales September 28, 2024 September 30, 2023 % Change (1) (1) September 28, 2024 September 30, 2023 % Change (1) Change (1)
Skin Care $ 91.0 $ 86.7 5.0 % (0.4) % 4.6 % $ 333.5 $ 293.1 13.8 % 2.9 % 16.7 %
Upper
Respiratory 86.1 78.2 10.2 % (2.2) % 8.0 % 206.0 227.9 (9.6) % (1.3) % (10.9) %
Pain and
Sleep-Aids 56.9 61.1 (6.8) % (2.6) % (9.4) % 158.6 163.8 (3.2) % (2.1) % (5.3) %
Healthy
Lifestyle 53.2 52.4 1.4 % (1.5) % (0.2) % 175.2 179.4 (2.3) % 4.0 % 1.6 %
VMS 43.0 46.1 (6.8) % (1.1) % (7.9) % 127.4 135.4 (5.9) % (0.4) % (6.3) %
Women's
Health 32.2 28.5 13.0 % (1.3) % 11.7 % 101.2 89.5 13.1 % -- % 13.0 %
Oral Care 23.3 24.8 (5.9) % (1.8) % (7.7) % 75.0 75.5 (0.7) % (1.3) % (1.9) %
Digestive
Health and
Other CSCI 30.6 42.5 (28.3) % 1.1 % (27.2) % 108.5 116.1 (6.5) % 0.7 % (5.8) %
-------------------- -------------------- -------- -------- -------- ------------------- ------------------- -------- -------- -------------------
Total CSCI
Net
Sales $ 416.3 $ 420.3 (1.0) % (1.3) % (2.2) % $ 1,285.4 $ 1,280.7 0.4 % 0.7 % 1.0 %
Note: amounts may not add or recalculate due to rounding. Percentages are
based on actuals.
(1) Currency impact is calculated using the exchange rates used to
translate our financial statements in the comparable prior year period
to show what current period US dollar results would have been if such
currency exchange rates had not changed.
CSCI Third Quarter Primary Category Drivers:
-- Skin Care: Net sales of $91 million increased 5.0%, or an increase of
4.6% excluding the impact of currency, due to strong growth in Compeed$(R)$,
driven by market share gains, in addition to higher net sales within the
ACO(R) and Sebamed(R) brand portfolios. The category also benefited from
the absence of prior year distribution transitions.
-- Upper Respiratory: Net sales of $86 million increased 10.2%, or an
increase of 8.0% excluding the impact of currency, due primarily higher
net sales of Bronchenolo(R), Bronchostop(R) and Coldrex(R), which
benefited from category growth and market share gains.
-- Pain & Sleep-Aids: Net sales of $57 million decreased 6.8%, or a decrease
of 9.4% excluding the impact of currency, due primarily to lower net
sales of Solpadeine(R), due primarily to supply constraints, and lower
net sales of store brand products.
-- Healthy Lifestyle: Net sales of $53 million increased 1.4%, or a decrease
of 0.2% excluding the impact of currency, as higher consumption for
anti-parasite products including Paranix(R), were more than offset by
lower category consumption in weight loss, impacting XLS Medical(R).
-- VMS: Net sales of $43 million decreased 6.8%, or a decrease of 7.9%
excluding the impact of currency, due primarily to promotional phasing of
Davitamon(R) and Abtei(R) and overall lower category consumption.
-- Women's Health: Net sales of $32 million increased 13.0%, or an increase
of 11.7% excluding the impact of currency, due primarily to higher net
sales of contraceptive products including EllaOne(R), driven by market
share gains and the absence of prior year distribution transitions.
-- Oral Care: Net sales of $23 million decreased 5.9%, or a decrease of 7.7%
excluding the impact of currency, due primarily to lower net sales of
store brand products and Plackers(R).
-- Digestive Health and Other: Net sales of $31 million decreased 28.3%, or
a decrease of 27.2% excluding the impact of currency, primarily due to
the divestiture of the HRA Pharma Rare Diseases Business, which was
partially offset by higher net sales of store brand products.
TABLE VII
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
CONSOLIDATED AND SELECTED SEGMENT INFORMATION
(in millions, except per share amounts)
(unaudited)
Three Months Ended Nine Months Ended
Consolidated
Continuing September September September September
Operations 28, 2024 30, 2023 Total Change 28, 2024 30, 2023 Total Change
Adjusted gross
profit $ 446.1 $ 443.6 $ 2.5 0.6 %
Adjusted gross
margin 41.0 % 39.5 % 160 bps
Adjusted
operating
income $ 182.4 $ 150.3 $ 32.0 21.3 % $ 414.6 $ 407.2 1.8 %
Less:
Currency
impact(1) (3.3) --
---------- ----------
Constant
currency
adjusted
operating
income $ 417.9 $ 407.2 $ 10.7 2.6 %
Adjusted
operating
margin 16.8 % 13.4 % 340 bps
Adjusted EPS $ 0.81 $ 0.64 $ 0.17 26.6 %
Consumer
Self-Care
Americas
Adjusted gross
profit $ 235.1 $ 228.5 $ 6.6 2.9 %
Adjusted gross
margin 35.0 % 32.5 % 250 bps
Adjusted
operating
income $ 131.9 $ 108.1 $ 23.8 22.0 %
Adjusted
operating
margin 19.7 % 15.4 % 430 bps
Consumer
Self-Care
International
Adjusted gross
profit $ 211.1 $ 215.1 $ (4.0) (1.9) %
Adjusted gross (50)
margin 50.7 % 51.2 % bps
Adjusted
operating
income $ 91.9 $ 79.7 $ 12.2 15.3 %
Adjusted
operating
margin 22.1 % 19.0 % 310 bps
Note: amounts may not add or recalculate due to rounding. Percentages are
based on actuals.
(1) Currency impact is calculated using the exchange rates used to
translate our financial statements in the comparable prior year period
to show what current period US dollar results would have been if such
currency exchange rates had not changed.
View original content to download multimedia:https://www.prnewswire.com/news-releases/perrigo-reports-third-quarter-2024-financial-results-from-continuing-operations-302297423.html
SOURCE Perrigo Company plc
(END) Dow Jones Newswires
November 06, 2024 09:52 ET (14:52 GMT)
Comments